Exact Mass: 824.3466476000001
Exact Mass Matches: 824.3466476000001
Found 50 metabolites which its exact mass value is equals to given mass value 824.3466476000001,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
(2b,3b)-Dihydroxy-30-nor-12,20(29)-oleanadiene-28-glucopyranosyloxy-23-oic acid 3-glucuronide
(2b,3b)-Dihydroxy-30-nor-12,20(29)-oleanadiene-28-glucopyranosyloxy-23-oic acid 3-glucuronide is found in cereals and cereal products. (2b,3b)-Dihydroxy-30-nor-12,20(29)-oleanadiene-28-glucopyranosyloxy-23-oic acid 3-glucuronide is a constituent of Amaranthus cruentus (purple amaranth) Constituent of Amaranthus cruentus (purple amaranth). (2b,3b)-Dihydroxy-30-nor-12,20(29)-oleanadiene-28-glucopyranosyloxy-23-oic acid 3-glucuronide is found in cereals and cereal products and green vegetables.
6,7-Didehydrofevicordin F 3-[glucosyl-(1->6)-glucoside]
6,7-Didehydrofevicordin F 3-[glucosyl-(1->6)-glucoside] is found in fruits. 6,7-Didehydrofevicordin F 3-[glucosyl-(1->6)-glucoside] is a constituent of Cyclanthera pedata (achoccha) Constituent of Cyclanthera pedata (achoccha). 6,7-Didehydrofevicordin F 3-[glucosyl-(1->6)-glucoside] is found in fruits.
Aclacinomycin X
C42H52N2O15 (824.3367522000001)
D000970 - Antineoplastic Agents D007155 - Immunologic Factors
PGP(i-12:0/PGJ2)
C38H66O15P2 (824.3876746000001)
PGP(i-12:0/PGJ2) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(i-12:0/PGJ2), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of Prostaglandin J2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).
PGP(PGJ2/i-12:0)
C38H66O15P2 (824.3876746000001)
PGP(PGJ2/i-12:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(PGJ2/i-12:0), in particular, consists of one chain of one Prostaglandin J2 at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).
Aclacinomycin X
C42H52N2O15 (824.3367522000001)
D000970 - Antineoplastic Agents D007155 - Immunologic Factors
(3E,8E)-2alpha,7beta,9,10beta,13alpha,20-hexaacetoxy-5(2-acetoxy-cinnamoyloxy)-3,8-secotaxa-3,8,11-triene
4A-alpha-L-rhodinosyl-3-alpha-L-rhodinosyl-4C->1D-alpha-L-aculosylaquayamycin|saquayamycin K
4A-alpha-L-cinerulosyl-3-alpha-L-rhodinosyl-4C->1D-alpha-L-rhodinosylaquayamycin|saquayamycin J
3beta,11beta-Dihydroxy-12-oxo-18-nor-5alpha-card-13-enolid-3beta-O-(3-O-acetyl-beta-D-digitoxosido-beta-D-xylosido-alpha-L-rhamnosid)|3beta,11beta-Dihydroxy-12-oxo-18-nor-5alpha-card-13-enolid-3beta-O-<3-O-acetyl-beta-D-digitoxosido-beta-D-xylosido-alpha-L-rhamnosid>
(2b,3b)-Dihydroxy-30-nor-12,20(29)-oleanadiene-28-glucopyranosyloxy-23-oic acid 3-glucuronide
6,7-Didehydrofevicordin F 3-[glucosyl-(1->6)-glucoside]
DMT-dG(dmf)-CE-Phosphoramidite
DMT-dG(dmf) Phosphoramidite is a phosphinamide monomer that can be used in the preparation of oligonucleotides
[4R-(4alpha,5alpha,6alpha,7alpha)]-3,3-{{Tetrahydro-5,6-dihydroxy-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepine-1,3(2H)-diyl]bis(methylene)]bis[N-1H-benzimidazol-2-ylbenzamide]
C49H44N8O5 (824.3434493999999)
3,4,6,12,13-pentakis(acetyloxy)-8-hydroxy-4,8,11,11-tetramethyl-14-[(2-methylpropanoyl)oxy]-7,18-dioxo-19-oxatricyclo[13.4.0.0²,⁶]nonadec-9-en-15-yl 2-methylpropanoate
methyl (1r,2r,4s)-4-{[(2r,4s,5s,6s)-5-{[(2s,4s,5s,6s)-5-{[(2r,6s)-3-amino-6-methyl-5-oxo-2,6-dihydropyran-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-(dimethylamino)-6-methyloxan-2-yl]oxy}-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylate
C42H52N2O15 (824.3367522000001)
4-(6-{5,14-dimethyl-6-oxo-2,4,9,13-tetraoxatricyclo[8.4.0.0³,⁸]tetradecan-12-yl}-1,5-dihydroxy-9,10-dioxoanthracen-2-yl)-3-({5-[(5-hydroxy-6-methyloxan-2-yl)oxy]-6-methyloxan-2-yl}oxy)-3-methylbutanoic acid
4a,8,12b-trihydroxy-9-{4-hydroxy-6-methyl-5-[(6-methyl-5-oxooxan-2-yl)oxy]oxan-2-yl}-3-methyl-3-({6-methyl-5-[(6-methyl-5-oxooxan-2-yl)oxy]oxan-2-yl}oxy)-2,4-dihydrotetraphene-1,7,12-trione
(3s)-4-{6-[(1r,3r,5s,8s,10r,12r,14r)-5,14-dimethyl-6-oxo-2,4,9,13-tetraoxatricyclo[8.4.0.0³,⁸]tetradecan-12-yl]-1,5-dihydroxy-9,10-dioxoanthracen-2-yl}-3-{[(2s,5r,6s)-5-{[(2s,5r,6s)-5-hydroxy-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-3-methylbutanoic acid
methyl 2-[(1s,3s,5z,7r,8e,11s,12s,13e,15s,17r,21r,23r,25s)-12,25-bis(acetyloxy)-1,11,21-trihydroxy-17-[(1r)-1-hydroxyethyl]-13-(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1³,⁷.1¹¹,¹⁵]nonacos-8-en-5-ylidene]acetate
(11r,16s)-13-{2-[2,4-dihydroxy-5-(3-methylbut-2-en-1-yl)phenyl]-5-hydroxy-7,7-dimethylfuro[2,3-f]chromene-3-carbonyl}-5,14-dihydroxy-4,15-bis(3-methylbut-2-en-1-yl)-8,17-dioxatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁶]heptadeca-1(10),2,4,6,12,14-hexaen-9-one
4a,8,12b-trihydroxy-9-{4-hydroxy-5-[(5-hydroxy-6-methyloxan-2-yl)oxy]-6-methyloxan-2-yl}-3-methyl-3-({6-methyl-5-[(6-methyl-5-oxo-2,6-dihydropyran-2-yl)oxy]oxan-2-yl}oxy)-2,4-dihydrotetraphene-1,7,12-trione
(3r,4ar,12bs)-9-[(1r,3r,5s,8s,10r,12r,14r)-5,14-dimethyl-6-oxo-2,4,9,13-tetraoxatricyclo[8.4.0.0³,⁸]tetradecan-12-yl]-4a,8,12b-trihydroxy-3-{[(2s,5s,6s)-5-{[(2s,5s,6s)-5-hydroxy-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-3-methyl-2,4-dihydrotetraphene-1,7,12-trione
(2r,3r,4s,6r)-6-{[(1r,3br,5as,7s,9as,9bs,10r)-10-hydroxy-9a-methyl-11-oxo-1-[(3s)-5-oxooxolan-3-yl]-1h,2h,3h,3bh,4h,5h,5ah,6h,7h,8h,9h,9bh,10h-cyclopenta[a]phenanthren-7-yl]oxy}-3-{[(2s,3r,4r,5r)-3,4-dihydroxy-5-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-2-methyloxan-4-yl acetate
3-({3,4-dihydroxy-5-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl}oxy)-6-{[10-hydroxy-9a-methyl-11-oxo-1-(5-oxooxolan-3-yl)-1h,2h,3h,3bh,4h,5h,5ah,6h,7h,8h,9h,9bh,10h-cyclopenta[a]phenanthren-7-yl]oxy}-2-methyloxan-4-yl acetate
(1r,2r)-8-{[(2s,3r,4s,5s)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-2,7-dihydroxy-3a,6,9b,11a-tetramethyl-1-[(4e)-2,3,6-trihydroxy-6-methylhept-4-en-2-yl]-1h,2h,3h,3bh,11h-cyclopenta[a]phenanthren-10-one
(1r,2s,3e,5s,7r,8e,10r,13s)-2,7,9,10,13-pentakis(acetyloxy)-4-[(acetyloxy)methyl]-8,12,15,15-tetramethylbicyclo[9.3.1]pentadeca-3,8,11-trien-5-yl (2z)-2-(acetyloxy)-3-phenylprop-2-enoate
(3r,4ar,12bs)-4a,8,12b-trihydroxy-9-[(2r,4r,5s,6r)-4-hydroxy-5-{[(2s,5s,6s)-5-hydroxy-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl]-3-methyl-3-{[(2s,5s,6s)-6-methyl-5-{[(2r,6s)-6-methyl-5-oxo-2,6-dihydropyran-2-yl]oxy}oxan-2-yl]oxy}-2,4-dihydrotetraphene-1,7,12-trione
2,7,9,10,13-pentakis(acetyloxy)-4-[(acetyloxy)methyl]-8,12,15,15-tetramethylbicyclo[9.3.1]pentadeca-3,8,11-trien-5-yl 2-(acetyloxy)-3-phenylprop-2-enoate
9-{5,14-dimethyl-6-oxo-2,4,9,13-tetraoxatricyclo[8.4.0.0³,⁸]tetradecan-12-yl}-4a,8,12b-trihydroxy-3-({5-[(5-hydroxy-6-methyloxan-2-yl)oxy]-6-methyloxan-2-yl}oxy)-3-methyl-2,4-dihydrotetraphene-1,7,12-trione
(4s,7s,13r,22r)-2,5,8,11,14,20-hexahydroxy-4-(1h-indol-3-ylmethyl)-7-[(4-methoxy-1h-indol-3-yl)methyl]-13,18,22-trimethyl-16-methylidene-24-thia-3,6,9,12,15,18,21,26-octaazabicyclo[21.2.1]hexacosa-1(25),2,5,8,11,14,20,23(26)-octaen-17-one
C40H44N10O8S (824.3064144000001)
(11r,16s)-13-[5,6-dihydroxy-2-(7-hydroxy-2,2-dimethylchromen-6-yl)-7-(3-methylbut-2-en-1-yl)-1-benzofuran-3-carbonyl]-5,14-dihydroxy-4,15-bis(3-methylbut-2-en-1-yl)-8,17-dioxatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁶]heptadeca-1(10),2,4,6,12,14-hexaen-9-one
methyl 2-[12,25-bis(acetyloxy)-1,11,21-trihydroxy-17-(1-hydroxyethyl)-13-(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1³,⁷.1¹¹,¹⁵]nonacos-8-en-5-ylidene]acetate
2,5,8,11,14,20-hexahydroxy-4-(1h-indol-3-ylmethyl)-7-[(5-methoxy-1h-indol-3-yl)methyl]-13,18,22-trimethyl-16-methylidene-24-thia-3,6,9,12,15,18,21,26-octaazabicyclo[21.2.1]hexacosa-1(25),2,5,8,11,14,20,23(26)-octaen-17-one
C40H44N10O8S (824.3064144000001)
methyl (1r,2r,4s)-4-{[5-({5-[(3-amino-6-methyl-5-oxo-2,6-dihydropyran-2-yl)oxy]-4-hydroxy-6-methyloxan-2-yl}oxy)-4-(dimethylamino)-6-methyloxan-2-yl]oxy}-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylate
C42H52N2O15 (824.3367522000001)